• enterprise value to ebitda forward of celyad oncology sa – euronext:cyad TradingView Thu, 25 Jun 2026 17:44:55 GMT
• price to sales forward of celyad oncology sa – euronext:cyad TradingView Thu, 25 Jun 2026 15:38:46 GMT
• price to book forward of celyad oncology sa – euronext:cyad TradingView Thu, 25 Jun 2026 15:32:43 GMT
• prelude therapeutics appoints charles morris as chief medical officer MyChesCo Wed, 22 Apr 2026 07:00:00 GMT
• Prelude Therapeutics Names Charles Morris as Chief Medical Officer citybiz Wed, 15 Apr 2026 07:00:00 GMT
• prelude therapeutics announces the appointment of charles morris, m.d. as chief medical officer The Manila Times Wed, 15 Apr 2026 07:00:00 GMT
• celyad oncology reports €24.8 million net loss for 2025 and implements cost-saving measures to extend financial runway geneonline.com Thu, 02 Apr 2026 17:32:42 GMT
• cyad: returned to profitability in 2025 via asset sales, but future depends on ip monetization and new funding TradingView Thu, 02 Apr 2026 17:20:41 GMT
• Celyad Oncology Reports Full Year 2025 Financial Results and Business Highlights Business Wire Thu, 02 Apr 2026 07:00:00 GMT
• celyad oncology (1c0.mu) stock price, news, quote & history Yahoo! Finance Canada Thu, 02 Apr 2026 06:01:09 GMT
• ec approves indication extension for prostate cancer treatment option Pf Media Wed, 11 Mar 2026 10:57:38 GMT
• €0.486 surge: cyad.br (euronext) celyad oncology +38% on high volume, feb 2026 Meyka Fri, 20 Feb 2026 18:59:28 GMT
• down 28.48% intraday: cyad.br stock €0.35 on heavy volume, watch pipeline Meyka Wed, 18 Feb 2026 08:00:00 GMT
• celyad oncology sells c-cathez catheter to cellprothera in deal worth up to €5 million Pulse 2.0 Mon, 16 Feb 2026 08:00:00 GMT
• cyad.br celyad oncology euronext +34.93% intraday 16 feb 2026: high-volume alert Meyka Mon, 16 Feb 2026 08:00:00 GMT
• cellprothera acquires rights to celyad oncology’s transendocardial catheter Pf Media Fri, 13 Feb 2026 14:04:03 GMT
• cyad.br celyad oncology euronext +23.08% 12 feb 2026: volume spike hints momentum Meyka Fri, 13 Feb 2026 08:00:00 GMT
• CellProthera Acquires Full Rights to Transendocardial Catheter dicardiology.com Thu, 12 Feb 2026 08:00:00 GMT
• celyad oncology announces the sale of c-cathez ® catheter Business Wire Thu, 12 Feb 2026 08:00:00 GMT
• heart damage therapy moves toward phase 3 in €5m catheter sale Stock Titan Thu, 12 Feb 2026 06:00:00 GMT
• Celyad Oncology Announces the Sale of C-CATHez ® Catheter Business Wire Wed, 11 Feb 2026 08:00:00 GMT
• gene therapy for cancer market forecasted to reach usd 20.0 billion by 2035, at an impressive 12.6% cagr industrytoday.co.uk Tue, 10 Feb 2026 18:28:24 GMT
• car-t market leaders in 2026: leaders, innovators, and game-changing tech bioinformant.com Fri, 06 Feb 2026 08:00:00 GMT
• celyad oncology : reports full year 2025 financial results and business highlights marketscreener.com Wed, 04 Feb 2026 08:00:00 GMT
• celyad oncology sa reports earnings results for the full year ended december 31, 2025 marketscreener.com Wed, 04 Feb 2026 08:00:00 GMT
• oxford drug design announces further validation of novel oncology therapeutic mechanism Pf Media Wed, 14 Jan 2026 08:00:00 GMT
• storm therapeutics and alidabio collaborate to accelerate development of cancer therapies Pf Media Thu, 08 Jan 2026 08:00:00 GMT
• celyad oncology: publication of a transparency notification received from fortress investment group llc (article 14 §1 of the law ... Yahoo Finance Tue, 25 Nov 2025 08:00:00 GMT
• celyad oncology (cyad) discloses fortress at 67.77% rights after 65% threshold Stock Titan Tue, 25 Nov 2025 08:00:00 GMT
• celyad oncology: information on the total number of voting rights and shares (article 15 of the law of 2 may 2007) Business Wire Fri, 14 Nov 2025 08:00:00 GMT
• celyad (euronext: cyad) at 72,383,166 voting rights as 14,903,846 shares gain double Stock Titan Fri, 14 Nov 2025 08:00:00 GMT
• cnx therapeutics acquires sativex from jazz pharmaceuticals Pf Media Tue, 04 Nov 2025 08:00:00 GMT
• maxion therapeutics appoints dr. david gilham as chief business officer for antibody-based therapeutics geneonline.com Fri, 03 Oct 2025 06:36:43 GMT
• celyad oncology to sell belgian research facility for eur3 million 富途牛牛 Wed, 01 Oct 2025 19:27:19 GMT
• celyad oncology to sell belgian research facility for eur3 million 富途牛牛 Tue, 30 Sep 2025 07:00:00 GMT
• €3m research facility sale: celyad oncology extends cash runway through q3 2026 in strategic move Stock Titan Mon, 29 Sep 2025 16:30:00 GMT
• celyad oncology announces research facility divestiture Business Wire Mon, 29 Sep 2025 07:00:00 GMT
• celyad oncology to sell belgian research facility for eur3 million 富途牛牛 Mon, 29 Sep 2025 07:00:00 GMT
• celyad oncology reports first half year 2025 financial results Business Wire Thu, 25 Sep 2025 07:00:00 GMT
• cash position drops to €0.8m: celyad oncology reports increased r&d investment in cancer research Stock Titan Thu, 25 Sep 2025 07:00:00 GMT
• celyad oncology sa - publication of a transparency notification received from fortress investment group llc MarketScreener Fri, 12 Sep 2025 07:00:00 GMT
• 34.1m voting rights: fortress investment's control of biotech celyad oncology dips below key 60% threshold Stock Titan Thu, 11 Sep 2025 16:30:00 GMT
• celyad oncology sa: publication of a transparency notification received from fortress investment group llc (article 14 §1 of the l... Yahoo Finance Thu, 11 Sep 2025 07:00:00 GMT
• celyad oncology sa: information on the total number of voting rights and shares (article 15 of the law of 2 may 2007) Business Wire Thu, 04 Sep 2025 07:00:00 GMT
• 57.5 million voting rights: celyad oncology announces major share structure update with double rights Stock Titan Thu, 04 Sep 2025 07:00:00 GMT
• celyad oncology’s share structure and voting rights: implications for shareholder influence and corporate control AInvest Thu, 04 Sep 2025 05:11:29 GMT
• colorectal cancer pipeline outlook 2025: clinical trial studies, ema, pdma, fda approvals, moa, roa, nda, ind, and companies The Globe and Mail Mon, 01 Sep 2025 07:00:00 GMT
• Celyad Oncology Announces Discontinuation of R&D Activities Business Wire Tue, 26 Aug 2025 07:00:00 GMT
• incannex’s stock rallies on anxiety disorder data; appia bio closes its doors Endpoints News Tue, 26 Aug 2025 07:00:00 GMT
• celyad oncology announces discontinuation of r&d activities Business Wire Mon, 25 Aug 2025 07:00:00 GMT
• nice recommends astellas’ treatment for advanced bladder cancer Pf Media Thu, 21 Aug 2025 07:00:00 GMT
• celyad oncology sa: publication of a transparency notification received from fortress investment group llc Business Wire Wed, 13 Aug 2025 07:00:00 GMT
• fortress investment takes majority control of celyad oncology through $32.7m share acquisition Stock Titan Wed, 13 Aug 2025 07:00:00 GMT
• car t-cell therapy market to explode 1200%+ to $35.9 billion, forecast to 2032 newstrail.com Wed, 13 Aug 2025 07:00:00 GMT
• celyad oncology sa announces capital increase and update on total number of voting rights and shares AInvest Thu, 07 Aug 2025 16:36:23 GMT
• celyad oncology sa: information on the total number of voting rights and shares (article 15 of the law of 2 may 2007) Yahoo Finance Thu, 07 Aug 2025 07:00:00 GMT
• fortress investment group takes major stake in celyad oncology with 3.3m share investment Stock Titan Thu, 07 Aug 2025 07:00:00 GMT
• colorectal cancer pipeline outlook report 2025: key 195+ companies and breakthrough therapies shaping the future landscape Menafn Mon, 04 Aug 2025 07:07:12 GMT
• xtl biopharmaceuticals approves key resolutions at shareholder meeting AInvest Tue, 29 Jul 2025 07:00:00 GMT
• celyad oncology announces €1 million private placement Business Wire Mon, 28 Jul 2025 07:00:00 GMT
• celyad oncology just secured €1m investment as fortress set to control 58.5% stake Stock Titan Mon, 28 Jul 2025 07:00:00 GMT
• nice recommends novartis’ kisqali breast cancer combination therapy Pf Media Thu, 17 Jul 2025 07:00:00 GMT
• arbutus regains rights to hepatitis b asset in china; forte’s $75m offering Endpoints News Wed, 25 Jun 2025 07:00:00 GMT
• fortress biotech shares fall 1.68% intraday as celyad oncology reviews strategic alternatives. AInvest Wed, 25 Jun 2025 07:00:00 GMT
• celyad oncology explores strategic alternatives amid cash concerns by investing.com Investing.com Australia Wed, 25 Jun 2025 02:51:09 GMT
• celyad oncology explores strategic alternatives amid cash concerns Investing.com Tue, 24 Jun 2025 07:00:00 GMT
• from family funding to acquisition: esobiotec's success story BioXconomy Wed, 21 May 2025 07:00:00 GMT
• metastatic colorectal cancer market poised for expansion across the 7mm during the forecast period (2025-2034) as breakthrough the... PR Newswire Wed, 23 Apr 2025 07:00:00 GMT
• celyad oncology reports 2024 financial results and advances in car t-cell therapies MSN Sat, 05 Apr 2025 12:46:03 GMT
• celyad oncology reports 2024 financial results and advances in car t-cell therapies TipRanks Fri, 04 Apr 2025 07:00:00 GMT
• celyad oncology slashes cash burn 82% while pushing revolutionary cancer tech forward Stock Titan Wed, 02 Apr 2025 07:00:00 GMT
• celyad oncology reports full year 2024 financial results and recent business highlights Business Wire Wed, 02 Apr 2025 07:00:00 GMT
• three's a crowd as another kite exec hits the exit; surfing tough waters, celyad oncology picks up new ceo Endpoints News Sat, 29 Mar 2025 07:00:00 GMT
• car t-cell therapy market size to reach 27.5 billion by 2033 owing to rising awareness and favourable reimbursement policies says ... PR Newswire UK Wed, 26 Mar 2025 07:00:00 GMT
• astrazeneca pays up to $1bn for biotech firm ‘that could transform cell therapy’ The Guardian Mon, 17 Mar 2025 07:00:00 GMT
• tune’s ceo search ends as john mchutchison takes top spot; more from pfizer’s leadership makeover Endpoints News Fri, 07 Mar 2025 08:00:00 GMT
• illuccix gets approval in the uk to improve prostate cancer detection Pf Media Thu, 27 Feb 2025 08:00:00 GMT
• celyad oncology announces the publication of the preclinical and clinical data of cyad-211 providing proof-of-concept of its mirna... Business Wire Tue, 18 Feb 2025 08:00:00 GMT
• groundbreaking cancer treatment success: celyad's new car t-cell therapy shows zero gvhd cases in multiple myeloma trial Stock Titan Tue, 18 Feb 2025 08:00:00 GMT
• celyad oncology announces the publication of the preclinical and clinical data of cyad-211 providing proof-of-concept of its mirna... Business Wire Mon, 17 Feb 2025 08:00:00 GMT
• autologous cell therapy market is booming worldwide 2025-2032 | openPR Wed, 12 Feb 2025 03:53:00 GMT
• biomed x and daiichi sankyo collaboration calls for research proposals Pf Media Mon, 20 Jan 2025 08:00:00 GMT
• clyyf (celyad oncology) enterprise value : $17.61 mil (as of jan. 18, 2025) GuruFocus.com Sat, 18 Jan 2025 07:38:57 GMT
• exclusive: bucking gene editing downturn, tune raises $175m to bring epigenetic editing to clinic Endpoints News Sun, 12 Jan 2025 08:00:00 GMT
• 100 cell and gene therapy leaders to watch in 2025 Drug Discovery & Development Fri, 20 Dec 2024 08:00:00 GMT
• top daily losses: us stocks posting the largest losses today uk.finance.yahoo.com Mon, 16 Dec 2024 08:19:49 GMT
• allogeneic t cell therapies market report, 2024-2028 & 2033 GlobeNewswire Thu, 12 Dec 2024 08:00:00 GMT
• nice recommends az’s treatment for adults with resectable non-small cell lung cancer Pf Media Wed, 11 Dec 2024 08:00:00 GMT
• four new technologies that will change cancer treatment Labiotech.eu Tue, 10 Dec 2024 08:00:00 GMT
• adoptive cell therapy market size to hit $23,440.7 million by 2030, coherent market insights BioSpace Tue, 26 Nov 2024 08:00:00 GMT
• companies get creative with multi-targeted cars at sitc, ash BioCentury Thu, 21 Nov 2024 08:00:00 GMT
• evinature and crohn’s & colitis foundation form partnership Pf Media Wed, 20 Nov 2024 08:00:00 GMT
• Cancer Cell Market is Booming with Strong Growth Prospects 2024-2031 | Kite Pharma, Cellectis, Celyad Oncology EIN News Wed, 23 Oct 2024 07:00:00 GMT
• celyad oncology to present at the 2024 sitc annual meeting Business Wire Mon, 07 Oct 2024 07:00:00 GMT
• state of new jersey common pension fund d has $3.31 million stock holdings in caesars entertainment, inc. (nasdaq:czr) Defense World Wed, 18 Sep 2024 10:05:31 GMT
• another delaware publicly traded company proposes a nevada move The National Law Review Tue, 17 Sep 2024 14:28:31 GMT
• caesars entertainment inc’s latest rating changes from various analysts Knox Daily Tue, 17 Sep 2024 10:25:06 GMT
• belgium: kane to take up ceo role at celyad oncology in october Investors in Healthcare Tue, 17 Sep 2024 07:00:00 GMT
• daiwa securities group inc. grows position in caesars entertainment, inc. (nasdaq:czr) Defense World Mon, 16 Sep 2024 09:54:22 GMT
• choreo llc purchases 6,289 shares of caesars entertainment, inc. (nasdaq:czr) Defense World Mon, 16 Sep 2024 08:49:16 GMT
• celyad oncology announces appointment of matt kane as chief executive officer Business Wire Mon, 16 Sep 2024 07:00:00 GMT
• colorectal cancer treatment drugs, pipeline insights, and companies 2024 openPR Mon, 16 Sep 2024 03:46:00 GMT
• caesars entertainment, inc. (nasdaq:czr) shares bought by royal london asset management ltd. Defense World Sun, 15 Sep 2024 08:19:08 GMT
• celyad oncology reports first half year 2024 financial results and recent business highlights Business Wire Fri, 13 Sep 2024 07:00:00 GMT
• wedbush securities inc. invests $731,000 in caesars entertainment, inc. (nasdaq:czr) Defense World Thu, 12 Sep 2024 13:47:30 GMT
• ashton thomas private wealth llc increases stock holdings in caesars entertainment, inc. (nasdaq:czr) Defense World Thu, 12 Sep 2024 11:10:53 GMT
• autologous cell therapy products market industry trends, share, size and forecast report (2024-2034) Handheld Pipette Controller ... Mon, 09 Sep 2024 23:10:22 GMT
• autologous cell therapy products market size, innovations driving market evolution (2024-2034) Handheld Pipette Controller ... Mon, 09 Sep 2024 23:05:12 GMT
• colorectal cancer treatment drugs, clinical trials, and companies 2024 openPR Mon, 09 Sep 2024 05:40:00 GMT
• car-t cell funding market size, share, global trends and GlobeNewswire Mon, 26 Aug 2024 07:00:00 GMT
• idh inhibitor market to exhibit significant growth rate during the study period (2020–2034) | delveinsight GlobeNewswire Mon, 29 Jul 2024 07:00:00 GMT
• car t-cell therapy market size is set to grow by usd 3.02 billion from 2024-2028, growing awareness regarding car t-cell therapy t... The Malaysian Reserve Sat, 06 Jul 2024 07:00:00 GMT
• car t-cell therapy market size is set to grow by usd 3.02 billion from 2024-2028, growing awareness regarding car t-cell therapy t... PR Newswire Fri, 05 Jul 2024 07:00:00 GMT
• engineering strategies to safely drive car t-cells into the future Frontiers Wed, 19 Jun 2024 04:38:19 GMT
• celyad oncology provides fourth quarter 2023 business update and 2024 outlook br.ADVFN.com Thu, 30 May 2024 12:15:55 GMT
• cellistic and celyad oncology announce gmp cell therapy manufacturing operations transaction Quantisnow Thu, 30 May 2024 10:36:26 GMT
• aacr annual meeting 2018 - cyad-101-002, immuno-oncology The Pharma Letter Sun, 12 May 2024 08:19:14 GMT
• aacr annual meeting 2018 - cyad-101-002, biotechnology The Pharma Letter Sat, 11 May 2024 20:11:03 GMT
• ers international congress 2016 - cyad-101-002, biotechnology The Pharma Letter Tue, 07 May 2024 14:52:52 GMT
• celyad oncology reports full year 2023 financial results and recent business highlights Yahoo Finance Thu, 04 Apr 2024 07:00:00 GMT
• relapsed/refractory acute myeloid leukemia pipeline outlook report 2024 openPR Thu, 04 Apr 2024 07:00:00 GMT
• celyad oncology reports full year 2023 financial results and recent business highlights Yahoo Finance Wed, 03 Apr 2024 07:00:00 GMT
• global gmp cell therapy consumables market projected to GlobeNewswire Thu, 28 Mar 2024 07:00:00 GMT
• a cure for cancer? how car-t cell therapy is revolutionizing oncology Labiotech.eu Mon, 25 Mar 2024 07:00:00 GMT
• changing faces: pharma and biotech hires from february 2024 pharmaphorum Mon, 11 Mar 2024 07:00:00 GMT
Celyad Oncology SA(NASDAQ:CYAD) 
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical t...
Website: http://www.celyad.com
Founded: 2004
Full Time Employees: 105
Sector: Healthcare
Industry: Biotechnology